Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Meningitis
Conditions
Meningitis, Septicemia
Trial Timeline
Jun 1, 2009 → Oct 1, 2010
NCT ID
NCT00901940About Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo is a phase 3 stage product being developed by Novartis for Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00901940. Target conditions include Meningitis, Septicemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00901940 | Phase 3 | Completed |
Competing Products
20 competing products in Meningitis